Tyromotion

Tyromotion operates in medical devices and rehabilitation robotics, selling robotic-assisted and sensor-based systems for clinical rehabilitation. Its portfolio spans hand and upper-limb therapy, gait training, balance, standing, and lower-limb exercise, giving it broader modality coverage than a company focused on a single rehabilitation device. Products such as AMADEO, LEXO, MYRO, and OMEGO Plus pair dedicated therapeutic hardware with biofeedback, sensor-based interaction, or task-oriented exercises. The company also offers products intended for children as well as adults, and its systems are complemented by therapist training, clinical application support, maintenance, and service. Market coverage that mentions Tyromotion also names companies including AlterG, Bionik Laboratories, Ekso Bionics, and Hocoma; that establishes a relevant market landscape, but does not by itself show direct product equivalence or relative market share. Its differentiation is most evident in the breadth of its rehabilitation equipment and the integration of robotic assistance, measurement, and interactive therapy features.

Tyromotion’s trajectory is characterized by a substantial operating history and a wide product range, with limited public detail about recent growth rates or financing. Founded in 2007 in Graz, the company has developed equipment across hand and upper-limb rehabilitation, gait training, balance, supported standing, and lower-limb therapy. Its Jun 23, 2016 seed round, which involved SHS Capital, is the only funding round listed, and the amount is undisclosed. A Jun 29, 2021 patent publication concerning wrist and finger training provides a specific marker of continuing technical development, while the available product lineup includes AMADEO, DIEGO, MYRO, PABLO, LEXO, and OMEGO Plus. Hiring across operations, sales, administration, engineering, and development suggests staffing needs in both commercial and product functions; the stated employee band is 101–250. These signals point to an established medical-device manufacturer extending and supporting a multi-product platform, rather than a newly financed startup. The clearest inflection points are its 2016 seed financing and subsequent expansion of a portfolio that addresses multiple rehabilitation settings.